12. CONFLICT OF INTEREST
All members of the Muscle-Invasive and Metastatic Bladder Cancer Guidelines Working Group have provided disclosure statements of all relationships that they have that might be perceived as a potential source of a conflict of interest. This information is publicly accessible through the EAU website: https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer/panel.
This Guidelines document was developed with the financial support of the EAU. No external sources of funding and support have been involved. The EAU is a non-profit organisation, and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.
Disclosures: The EAU Guidelines Office certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g. employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following:
A.G. van der Heijden reported receiving company speaker honoraria fees from Merck Sharp & Dohme B.V.; and serving as a company consultant to Astellas Pharma International B.V., Johnson & Johnson Innovative Medicine, Merck Sharp & Dohme B.V. and Pfizer B.V. A. Carrión reported receiving company speaker honoraria, travel or consultation fees from Johnson & Johnson, Gebro, BMS and BC Platform; serving as a company consultant to BC Platforms; and participation in clinical trials by Janssen Research & Development, LLC. R. Cathomas reported receiving company speaker honoraria or consultation fees from Astellas, Astra Zeneca, Bayer, BMS, Johnson & Johnson, MSD, Pfizer, Roche, Merck Serono and Ipsen. E.M. Compérat reported serving as a company consultant to Daiitchi, Johnson and Astra. K. Dimitropoulos reported receiving company speaker honoraria fees from Astellas and Ipsen. J.A. Efstathiou reported receiving company speaker honoraria or consultation fees from Astellas; and serving as a company consultant for Boston Scientific and Blue Eagle Diagnostics. B. Kiss reported serving as a company consultant on the advisory board of Pfizer and Astra Zeneca. A. Lorch reported receiving company speaker honoraria or consultation fees from Astellas, Astra Zeneca, Bayer, BMS, Esai, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer and Roche; receiving travel grants from Ipsen, Janssen and Bayer; participation in clinical trials as a principal investigator; and contributing as an author to the Onkopedia guidelines. P. Mariappan reported receiving company speaker honoraria fees from Bristol Myers Squibb, Janssen Cilag Ltd., Medac Pharma and Photocure; serving on the core committee of the International Bladder Cancer Group; receiving grants or research support from Nucleix; and participation in clinical trials by Nucleix. R.P. Meijer reported receiving grants or research support from Astellas Pharma International B.V., Gilead Sciences, Janssen Vaccines & Prevention B.V. and Merck Sharp & Dohme B.V. L.S. Mertens reported receiving company speaker honoraria fees from Johnson & Johnson Medical B.V and MSD (paid to hospital). M.I. Milowsky reported receiving grants or research support from Merck, Bristol-Myers Squibb, Alliance for Clinical Trials in Oncology, ALX Oncology, Novartis, Acrivon Therapeutics, PCCTC, OncoC4, Flare Therapeutics, Loxo/Lilly, Astellas Pharma, Pfizer, Amgen, Roche and G1 Therapeutics; being a stock shareholder in Pfizer and Gilead Sciences; presenting continuing medical education at Prime Education, Research to Practice and OncLive/MJH Life Sciences; and acting as uncompensated advisor to G1 Therapeutics and Loxo/Lilly. Y. Neuzillet reported receiving company speaker honoraria or consultation fees from AstraZeneca, Bristol-Myers Squibb, Merck, Astellas and MSD. M. Rink reported receiving company speaker honoraria fees from Johnson & Johnson, Astellas, AstraZeneca, Bayer, BMS, EUSA, Eisai, Ipsen, Medac, Merck Healthcare, MSD, Olympus, Pfizer, Photocure and Roche; serving as a company consultant to Olympus, Johnson & Johnson, BMS, Bayer, Boston Scientific, Eisai, Ipsen, Merck Healthcare, MSD, Pfizer and Roche; and participation in clinical trials by Aveo Pharmaceuticals, BMS, Calithera Bioscience, Excelixis, Ipsen, MSD, Merck Healthcare, Novartis, Pfizer and Roche. J. Shaw reported being an unremunerated trustee of Fight Bladder Cancer, a United Kingdom charity organisation. A. Martini reported receiving company speaker honoraria or consultation fees from Ferring Pharma and UroGen Pharma; and being a stock shareholder in a non-public company. H.M. Bruins, R. Fietkau, V. Panebianco, G.N. Thalmann, S. Sæbjørnsen and M. Kailavasan have nothing to declare.